Latest News and Press Releases

Facility to Support Allogeneic CAR T, Gene Therapy, and Stem Cell-Derived Therapies Facility Able to Support Clinical Trial and Early Commercial Launches of Multiple Programs State-of-the-Art...

First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression Transplanting allogeneic cells into a...

SEATTLE , June 14, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be...

SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...

Presented key proof of concept data for multiple platforms at AACR 2021 Q1 2021 cash position of $981.9 million SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a...

SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...

— Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes — SEATTLE, April 27, 2021 (GLOBE NEWSWIRE)...

– Targeted in vivo gene delivery of a CAR using a CD8-specific fusogenresults in tumor eradication –– Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in...

Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of $412 million Further strengthened cash position with $627 million in net IPO proceeds SEATTLE,...

MADISON, Wis. and SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC)...